Merus N.V. (MRUS) PT Raised to $33 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Merus N.V. (MRUS) Prices 3.86M Share Offering at $28.50/sh
November 5, 2021 5:39 AM EDTMerus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics), today announced the pricing of an underwritten public offering of 3,859,650 common shares, at a public offering price of $28.50 per share (the Offer Shares). Merus also granted the underwriters a 30-day option to purchase up to an additional 578,947 common shares (the Option Shares and together with the Offer Shares, the Shares). The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses and excluding the underwriters option to purchase the Option Shares, are approximately $110.0 million.... More
Merus N.V. (MRUS) Announces Proposed Stock Offering, Size not Disclosed
November 4, 2021 4:09 PM EDTMerus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the launch of a proposed underwritten public offering of its common shares (the Offer Shares). All of the common shares are being offered by Merus. In addition, Merus expects to grant the underwriters a 30-day option to purchase an additional 15% of the Offer Shares (the Option Shares and together with the Offer Shares, the Shares). The offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or... More
